London
· Delayed Price · Currency is GBP · Price in USDGilead Sciences Statistics
Total Valuation
Gilead Sciences has a market cap or net worth of GBP 91.76 billion. The enterprise value is 104.86 billion.
| Market Cap | 91.76B |
| Enterprise Value | 104.86B |
Important Dates
The next estimated earnings date is Monday, February 3, 2025.
| Earnings Date | Feb 3, 2025 |
| Ex-Dividend Date | Dec 13, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.91% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 1.24B |
Valuation Ratios
The trailing PE ratio is 976.10.
| PE Ratio | 976.10 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.34, with an EV/FCF ratio of 14.90.
| EV / Earnings | 1,115.43 |
| EV / Sales | 4.66 |
| EV / EBITDA | 9.34 |
| EV / EBIT | 11.78 |
| EV / FCF | 14.90 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 1.26.
| Current Ratio | 1.26 |
| Quick Ratio | 0.96 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | 1.65 |
| Debt / FCF | 2.47 |
| Interest Coverage | 11.42 |
Financial Efficiency
Return on equity (ROE) is 0.56% and return on invested capital (ROIC) is 15.74%.
| Return on Equity (ROE) | 0.56% |
| Return on Assets (ROA) | 11.96% |
| Return on Capital (ROIC) | 15.74% |
| Revenue Per Employee | 1.17M |
| Profits Per Employee | 5,223 |
| Employee Count | 18,000 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 3.56 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +17.91% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +17.91% |
| 50-Day Moving Average | 90.86 |
| 200-Day Moving Average | 77.10 |
| Relative Strength Index (RSI) | 53.48 |
| Average Volume (20 Days) | 79,639 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.50 |
Income Statement
In the last 12 months, Gilead Sciences had revenue of GBP 21.11 billion and earned 94.01 million in profits. Earnings per share was 0.07.
| Revenue | 21.11B |
| Gross Profit | 16.43B |
| Operating Income | 8.35B |
| Pretax Income | 132.06M |
| Net Income | 94.01M |
| EBITDA | 10.41B |
| EBIT | 8.35B |
| Earnings Per Share (EPS) | 0.07 |
Balance Sheet
The company has 5.00 billion in cash and 17.35 billion in debt, giving a net cash position of -12.35 billion.
| Cash & Cash Equivalents | 5.00B |
| Total Debt | 17.35B |
| Net Cash | -12.35B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 13.72B |
| Book Value Per Share | 11.06 |
| Working Capital | 2.28B |
Cash Flow
In the last 12 months, operating cash flow was 7.48 billion and capital expenditures -440.95 million, giving a free cash flow of 7.04 billion.
| Operating Cash Flow | 7.48B |
| Capital Expenditures | -440.95M |
| Free Cash Flow | 7.04B |
| FCF Per Share | n/a |
Margins
Gross margin is 77.80%, with operating and profit margins of 39.53% and 0.45%.
| Gross Margin | 77.80% |
| Operating Margin | 39.53% |
| Pretax Margin | 0.63% |
| Profit Margin | 0.45% |
| EBITDA Margin | 49.29% |
| EBIT Margin | 39.53% |
| FCF Margin | 33.33% |
Dividends & Yields
This stock pays an annual dividend of 2.41, which amounts to a dividend yield of 2.59%.
| Dividend Per Share | 2.41 |
| Dividend Yield | 2.59% |
| Dividend Growth (YoY) | 0.28% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 3,085.71% |
| Buyback Yield | 0.91% |
| Shareholder Yield | 3.50% |
| Earnings Yield | 0.10% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Gilead Sciences has an Altman Z-Score of 3.09.
| Altman Z-Score | 3.09 |
| Piotroski F-Score | n/a |